Protagonist Therapeutics/$PTGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Ticker
$PTGX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
124
ISIN
US74366E1029
Website
PTGX Metrics
BasicAdvanced
$3.3B
62.51
$0.86
2.64
-
Price and volume
Market cap
$3.3B
Beta
2.64
52-week high
$60.60
52-week low
$30.67
Average daily volume
892K
Financial strength
Current ratio
17.255
Quick ratio
17.129
Long term debt to equity
1.421
Total debt to equity
1.649
Profitability
EBITDA (TTM)
28.053
Gross margin (TTM)
100.00%
Net profit margin (TTM)
27.04%
Operating margin (TTM)
13.10%
Effective tax rate (TTM)
1.57%
Revenue per employee (TTM)
$1,680,000
Management effectiveness
Return on assets (TTM)
2.48%
Return on equity (TTM)
8.99%
Valuation
Price to earnings (TTM)
62.514
Price to revenue (TTM)
16.112
Price to book
4.85
Price to tangible book (TTM)
4.85
Price to free cash flow (TTM)
9.986
Free cash flow yield (TTM)
10.01%
Free cash flow per share (TTM)
539.97%
Growth
Revenue change (TTM)
-34.02%
Earnings per share change (TTM)
-68.10%
3-year revenue growth (CAGR)
64.26%
3-year earnings per share growth (CAGR)
-30.61%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
Bulls say / Bears say
Protagonist Therapeutics reported a significant increase in total revenue to $434.4 million in 2024, up from $60 million in 2023, primarily due to milestone payments from partnerships with Takeda and Johnson & Johnson. (finanzwire.com)
The company's lead programs, including the Phase 3 VERIFY trial for rusfertide in polycythemia vera and the Phase 2b ANTHEM study for icotrokinra in ulcerative colitis, are approaching pivotal data readouts in March 2025, potentially leading to significant market opportunities. (medpath.com)
Protagonist has a robust cash position, with $559 million in cash, cash equivalents, and marketable securities as of the end of 2024, providing financial stability to advance its pipeline. (panabee.com)
The company reported a net loss of $79 million in 2023 and has an accumulated deficit of $340 million, indicating ongoing financial challenges. (panabee.com)
Protagonist's total liabilities increased significantly to approximately $69.43 million in 2024 from around $21.3 million in 2023, suggesting a substantial rise in debt. (thax.io)
The company's operating expenses grew to $181.6 million in 2024, up from $153.7 million in 2023, reflecting increased costs that could impact profitability. (biospace.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
PTGX News
AllArticlesVideos
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Business Wire·3 weeks ago
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Accesswire·4 weeks ago
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protagonist Therapeutics stock?
Protagonist Therapeutics (PTGX) has a market cap of $3.3B as of June 20, 2025.
What is the P/E ratio for Protagonist Therapeutics stock?
The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 62.51 as of June 20, 2025.
Does Protagonist Therapeutics stock pay dividends?
No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Protagonist Therapeutics dividend payment date?
Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) has a beta rating of 2.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.